Dynatronics said late last month it tapped former NinePoint Medical CEO Christopher von Jako as its new chief executive officer and board member, succeeding Kelvyn Cullimore Jr. who will stay on the company’s board of directors. Prior to joining Dynatronics, von Jako acted as prez & CEO of NinePoint Medical. Before joining Nine Point, von Jako also […]
Pavmed lands $10m from oversubscribed rights offering
Pavmed (NSDQ:PAVM) said today that it expects to reel in $10.4 million in gross proceeds from an oversubscribed rights offering that expired this week. The New York-based company received subscriptions exceeding the number of rights available under the offering, Pavmed said, adding that it anticipates the offering will close on June 12. Get the full story […]
PavMed subsidiary Lucid Dx inks licensing deal with Case Western Univ.
Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics said today it finalized a licensing agreement with Case Western Reserve University to commercialize its EsoCheck non-invasive cell sampling device and DNA biomarker test. The New York-based company said that the EsoCheck device has been shown to effectively and accurately detect Barrett’s Esophagus, which is a precursor to the most common […]
Pavmed registers for $20m rights offering
Pavmed (NSDQ:PAVM) said today that it filed a preliminary prospectus with the SEC for an offering of the rights to buy a new unit in exchange for each share of outstanding common stock. The medical device company plans to offer the rights to purchase up to 9 million units at $2.25 apiece on May 21, valuing […]
7 medtech stories we missed this week: April 27, 2018
From DuPuy Synthes’s spinal implant launch to Lumendi’s FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. DePuy Synthes launches spinal implants DePuy Synthes announced in an April 26 press release that it has launched its Proti 360º integrated titanium family of interbody devices that are designed […]
Pavmed closes warrant exchange offer
Pavmed Inc. (NSDQ:PAVM) said today that it closed its offer to exchange two Series W warrants for a single Z warrant. Approximately 10,151,682 Series W warrants were tendered and not withdrawn, which represents 96.4% of outstanding Series W warrants, the New York-based company said. Get the full story at our sister site, Drug Delivery Business News.
Pavmed reports prelim results of warrant exchange offer
Pavmed Inc. (NSDQ:PAVM) today reported the preliminary results of its offer to exchange two Series W warrants for a single Z warrant. Approximately 10,151,682 Series W warrants were tendered and not withdrawn, which represents 96.4% of outstanding Series W warrants, the New York-based company said. Get the full story at our sister site, Drug Delivery Business News. […]
Pavmed extends Series W warrant exchange offer through April
Pavmed Inc. (NSDQ:PAVM) said last week it plans to extend its previously announced offering to exchange two Series W warrants for a single Series Z warrant. The offering from the New York-based company is now extended through to April 2, having previously been set to close today at midnight, according to a press release. Read the […]
Pavmed floats exchange offer for discounted Series W shares
Pavmed Inc. (NSDQ:PAVM) today offered to trade a pair of its just-sold Series W warrants for a single Series Z unit worth $5.oo apiece. The New York-based company previously offered the opportunity for investors to exercise the Series W warrants at a discounted price of $2.00 per share. As of Feb. 8, Pavmed said 34,345 Series W warrants […]
Pavmed closes $4m offering
Pavmed (NSDQ:PAVM) said today it closed a previously announced public offering, raising approximately $3.9 million which it plans to use for working capital and general corporate purposes. Money raised in the round came through the sale of 2.4 million shares of its common stock at a price of $1.80 per share, the New York City-based company […]
Pavmed prices $4.3m offering
Pavmed (NSDQ:PAVM) today priced an underwritten public offering of 2,415,278 shares of its common stock at $1.80 per share. The New York City-based company said it would grant the offering’s underwriters a 45-day option to buy up to 362,292 additional shares of common stock to cover over-allotments. Pavmed expects to bring in $3.9 million in net […]
